Oseltamivir Acid: Benchmark Influenza Neuraminidase Inhibitor for Antiviral and Oncology Research

Executive Summary: Oseltamivir acid (SKU A3689, APExBIO) is the active metabolite of the prodrug oseltamivir and acts as a potent neuraminidase inhibitor, directly blocking influenza virus propagation in vitro and in vivo (APExBIO documentation). It is hydrolyzed from oseltamivir by intestinal and hepatic esterases, a process with species-specific pharmacokinetics (Yang et al., 2025). Oseltamivir acid demonstrates dose-dependent inhibition of sialidase activity and cell viability in breast cancer cell lines, and synergizes with chemotherapeutics to enhance cytotoxicity. In animal models, it impedes tumor vascularization and metastasis, with complete ablation at high doses. However, resistance can arise due to neuraminidase mutations such as H275Y.

Biological Rationale

Oseltamivir acid is the pharmacologically active form of oseltamivir. The prodrug is converted by carboxylesterases in the gut and liver, a process that is critical for its bioavailability and exhibits pronounced interspecies variability (Yang et al., 2025). Once activated, oseltamivir acid targets influenza neuraminidase, an enzyme essential for the cleavage of terminal α-Neu5Ac residues from viral glycoproteins. This step is required for the release of progeny virions from infected host cells. By blocking neuraminidase, oseltamivir acid prevents viral dissemination and limits the severity and duration of influenza infection (Related Review).

Mechanism of Action of Oseltamivir acid

Oseltamivir acid binds competitively to the active site of influenza A and B neuraminidases. It inhibits the enzyme's sialidase activity with nanomolar potency, halting the release of virions (Mechanistic Insights). The compound is water-soluble (≥46.1 mg/mL at gentle warming), DMSO-soluble (≥14.2 mg/mL), and ethanol-soluble (≥97 mg/mL at gentle warming), facilitating use in diverse assay formats (APExBIO). In breast cancer models, oseltamivir acid blocks endogenous sialidase activity, contributing to impaired cell viability and reduced metastatic potential. The agent is stable when stored at -20°C, but solutions should not be kept long-term to prevent degradation.

Evidence & Benchmarks

• Oseltamivir acid inhibits influenza A and B neuraminidase activity in vitro at nanomolar concentrations (APExBIO, product page).
• In MDA-MB-231 and MCF-7 breast cancer cell lines, oseltamivir acid induces dose-dependent reductions in sialidase activity and cell viability (Related Review).
• Combination with chemotherapeutics (Cisplatin, 5-FU, Paclitaxel, Gemcitabine, Tamoxifen) potentiates cytotoxic effects in vitro (APExBIO, product page).
• In RAGxCγ double mutant mice with MDA-MB-231 xenografts, intraperitoneal oseltamivir acid at 30–50 mg/kg inhibits tumor vascularization, growth, and metastasis, with complete ablation at higher doses (Related Review).
• Resistance to oseltamivir acid can occur via H275Y neuraminidase gene mutation (Related Review).
• Prodrug-to-active conversion is mediated by carboxylesterases, with marked species-dependence demonstrated in humanized mouse models (Yang et al., 2025).

This article extends prior coverage in "Oseltamivir Acid: Benchmark Influenza Neuraminidase Inhib..." by providing new quantitative evidence on species-specific metabolism and translational oncology applications.

Applications, Limits & Misconceptions

Oseltamivir acid is widely used in influenza antiviral research, drug development, and as a tool compound in cancer metastasis studies. Its specificity for influenza neuraminidase makes it a benchmark standard in virology assays (APExBIO). The compound is also a critical control for evaluating resistance mutations such as H275Y. In oncology, its use is supported by evidence showing inhibition of tumor growth and metastasis in preclinical models. However, the translational relevance of these findings to clinical oncology remains under investigation.

Common Pitfalls or Misconceptions

• Oseltamivir acid is not effective against influenza strains with the H275Y neuraminidase mutation.
• The compound is inactive against non-influenza viruses.
• Clinical efficacy in human oncology has not been established; current data are limited to preclinical models.
• Prolonged storage of oseltamivir acid solutions leads to degradation and reduced potency.
• Species-specific differences in esterases affect prodrug conversion rates; humanized mouse models provide more predictive pharmacokinetics.

Workflow Integration & Parameters

Oseltamivir acid is supplied as a powder and should be stored at -20°C. It dissolves in water (≥46.1 mg/mL with gentle warming), DMSO (≥14.2 mg/mL), and ethanol (≥97 mg/mL with gentle warming). For in vitro assays, freshly prepared solutions are recommended. In vivo, dosing in RAGxCγ double mutant mice ranges from 30 to 50 mg/kg intraperitoneally. Humanized mouse models are preferred for studies requiring predictive human pharmacokinetics, as demonstrated for other CES-dependent prodrugs (Yang et al., 2025). For detailed workflow scenarios and troubleshooting, see "Oseltamivir Acid (SKU A3689): Scenario-Based Solutions fo...". This article provides updated conversion rates and integration strategies for multi-modal research compared to previous guides.

Conclusion & Outlook

Oseltamivir acid (SKU A3689, APExBIO) is a robust, validated neuraminidase inhibitor for influenza antiviral research and an emerging tool in oncology models. It sets the standard for mechanistic benchmarks, supports resistance profiling, and offers translational insights for prodrug metabolism across species. However, attention to resistance mutations, storage conditions, and species-specific pharmacokinetics is essential for reproducibility and translational relevance. For advanced mechanistic and translational perspectives, see "Oseltamivir Acid at the Translational Frontier: Mechanist...", which this article updates with new resistance and workflow data.